Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
Osteoporosis, Prostate Cancer
About this trial
This is an interventional supportive care trial for Osteoporosis focused on measuring osteoporosis, stage I prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: History of prostate cancer No evidence of metastatic bony disease* NOTE: *Elevated prostate-specific antigen (PSA) allowed Meets one of the following criteria: Currently on treatment with androgen-ablation therapy in the adjuvant setting Rising PSA without other evidence of recurrent disease with planned treatment for at least 6 months No known osteoporosis or prior osteoporotic fracture Osteoporosis defined as bone density at the hip or spine of more than 2.5 standard deviations below the mean for young men PATIENT CHARACTERISTICS: Age 18 and over Performance status Not specified Life expectancy Not specified Hematopoietic Not specified Hepatic SGOT or SGPT no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase normal OR no greater than 1.5 times ULN with a normal bone scan Renal Creatinine no greater than 1.5 times ULN No prior symptomatic hypercalcemia or hypocalcemia Cardiovascular No active heart disease No congestive heart failure under active treatment No myocardial infarction within the past 5 years No coronary artery disease (CAD) with recent myocardial infarction Patients with a remote history of CAD who are only on medical treatment (e.g., antilipid agents) are allowed No prior thrombosis (deep vein thrombosis, stroke, or pulmonary embolism) or other known hypercoagulable state other than cancer Other Fertile patients must use effective contraception Triglycerides no greater than 250 mg/dL (treatment allowed) Able to complete questionnaire(s) by self or with assistance Able to swallow pills No prior hyperlipidemia (e.g., prior familial hyperlipidemia or fasting triglyceride greater than 250 mg/dL within the past 6 months) No sarcoidosis No parathyroid dysfunction No intolerance to bisphosphonates PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No concurrent chemotherapy Endocrine therapy See Disease Characteristics No concurrent systemic steroids Radiotherapy No concurrent radiotherapy Surgery More than 3 months since prior and no concurrent dental extraction, root canal, or dental implantation Other No prior bisphosphonates More than 5 years since prior percutaneous transluminal coronary angioplasty
Sites / Locations
- CCOP - Mayo Clinic Scottsdale Oncology Program
- Mayo Clinic - Jacksonville
- Rush-Copley Cancer Care Center
- St. Joseph Medical Center
- Graham Hospital
- Memorial Hospital
- Eureka Hospital
- Galesburg Clinic
- Galesburg Cottage Hospital
- InterCommunity Cancer Center of Western Illinois
- Mason District Hospital
- Hopedale Medical Complex
- Joliet Oncology Hematology Associates, Limited - West
- Kewanee Hospital
- McDonough District Hospital
- BroMenn Regional Medical Center
- Community Cancer Center
- Community Hospital of Ottawa
- Oncology Hematology Associates of Central Illinois - Ottawa
- Cancer Treatment Center at Pekin Hospital
- Methodist Medical Center of Illinois
- Proctor Hospital
- CCOP - Illinois Oncology Research Association
- Oncology/Hematology Associates of Central Illinois, P.C.
- OSF St. Francis Medical Center
- Illinois Valley Community Hospital
- Perry Memorial Hospital
- St. Margaret's Hospital
- Valley Cancer Center
- Carle Cancer Center at Carle Foundation Hospital
- CCOP - Carle Cancer Center
- Saint Anthony Memorial Health Centers
- McFarland Clinic, P.C.
- Saint Anthony Regional Hospital
- Alegent Health Mercy Hospital
- Mercy Capitol Hospital
- CCOP - Iowa Oncology Research Association
- John Stoddard Cancer Center at Iowa Methodist Medical Center
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
- Medical Oncology and Hematology Associates at Mercy Cancer Center
- Mercy Cancer Center at Mercy Medical Center - Des Moines
- John Stoddard Cancer Center at Iowa Lutheran Hospital
- Mercy Cancer Center at Mercy Medical Center - North Iowa
- Alegent Health Community Memorial Hospital
- Burgess Health Center
- Cancer Center at Ottumwa Regional Health Center
- Siouxland Regional Cancer Center
- Siouxland Hematology-Oncology Associates
- Mercy Medical Center - Sioux City
- St. Luke's Regional Medical Center
- Medical Oncology and Hematology Associates - West Des Moines
- Cancer Center of Kansas - Chanute
- Cancer Center of Kansas - Dodge City
- Cancer Center of Kansas, P.A. - El Dorado
- Cancer Center of Kansas - Kingman
- Southwest Medical Center
- Cancer Center of Kansas - Newton
- Cancer Center of Kansas, P.A. - Parsons
- Pratt Cancer Center of Kansas
- Cancer Center of Kansas - Salina
- Cancer Center of Kansas - Wellington
- Associates in Womens Health
- Cancer Center of Kansas, P.A.
- Cancer Center of Kansas, P.A. - Wichita
- CCOP - Wichita
- Via Christi Cancer Center at Via Christi Regional Medical Center
- Cancer Center of Kansas - Winfield
- Brainerd Medical Center
- Fairview Ridges Hospital
- Mercy Hospital
- CCOP - Duluth
- Miller-Dwan Medical Center
- St. Mary's - Duluth Clinic Cancer Center
- Fairview Southdale Hospital
- Mercy and Unity Cancer Center at Mercy and Unity Hospitals
- Virginia Piper Cancer Institute at Abbott-Northwestern Hospital
- Hubert H. Humphrey Cancer Center at North Memorial Medical Center
- Mayo Clinic Cancer Center
- CCOP - Metro-Minnesota
- CentraCare Clinic - River Campus
- Park Nicollet Clinic
- United Hospital
- Ridgeview Medical Center
- Rice Memorial Hospital
- CCOP - Montana Cancer Consortium
- Great Falls Clinic
- Sletten Regional Cancer Institute
- Fremont Area Medical Center
- Bryan LGH Medical Center West
- Cancer Resource Center - Lincoln
- St. Elizabeth Regional Medical Center
- CCOP - Missouri Valley Cancer Consortium
- Immanuel Medical Center
- Bergan Mercy Medical Center
- Cancer Center at Creighton University Medical Center
- Midlands Cancer Center at Midlands Community Hospital
- Rutherford Hospital
- Bismarck Cancer Center
- Medcenter One Health System
- Mid Dakota Clinic, P.C.
- St. Alexius Medical Center
- Altru Cancer Center at Altru Hospital
- Natalie Warren Bryant Cancer Center at St. Francis Hospital
- Geisinger Medical Center
- Geisinger Medical Group
- Geisinger Wyoming Valley Medical Center
- Rose Ramer Cancer Clinic at Anderson Area Medical Center
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
- CCOP - Upstate Carolina
- Sioux Valley Hospital and University of South Dakota Medical Center
- Avera McKennan Hospital and University Health Center
- Medical X-Ray Center
- Pasqua Hospital
- Allan Blair Cancer Centre at Pasqua Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Experimental
Placebo Comparator
Experimental
Arm I: calcium + cholecalciferol + placebo + estrogen
Arm II: calcium + cholecalciferol + risedronate + estrogen
Arm III: calcium + cholecalciferol + placebo + estrogen
Arm IV: calcium + cholecalciferol + risedronate + estrogen
Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily. Treatment in all arms continues for 2 years. Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years. Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years.
Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily. Treatment in all arms continues for 2 years. Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years. Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years.
Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily. Treatment in all arms continues for 2 years. Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years. Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years.
Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily. Treatment in all arms continues for 2 years. Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years. Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years.